

Impact Developer & Contractor

The worst is behind us

We downgrade our recommendation for Impact Developer & Contractor to HOLD (from BUY), with a fair value per share of RON 0.20, implying a 5.5% upside from the current share price. The issues with the stock of unsold apartments have been resolved. We expect these apartments to be sold and recognized in revenue rather quickly, suggesting the difficult period Impact has gone through recently is a thing of the past. Combined with other developments in Romania, the company will smoothen out its real estate development cycle and report consistent revenue growth. At this time, Romania still has one of the highest overcrowding rates in Europe, indicating unmet demand. Additionally, the largest urban settlements in the country will likely experience population growth, even when accounting for the overall population decline. Impact targets a low to middle income segment, which matches the demographic type that will move in the respective urban areas. The company trades at 16.6X EV/EBITDA vs 7.8x peer median.

Overcrowding still an issue in Romania. The real estate demand is unment currently, as the country had an overcrowding rate of 44.7% in 2023, compared to the 18.1% EU27 average, based on Eurostat data, signalling that development should accelerate going forward. In this case, population decline in urban areas is offset by middle income young individuals and families, moving into the metropolitan areas of the country's largest urban centers..

The issue of unsold apartments solved. As a consequence of legal matters, the company was unable to sell and recognize in revenue over 700 apartments that it had finalized. it appears that the issue has been resolved, as indicated in one of the press statements. As such, we believe these apartments will be sold rather quickly in 1H25E, as some of them had delivery contracts signed with customers.

Real estate development cycle smoothened out. Going forward, the company will manage to smoothen out its development cycle, given the existing projects for which Impact has building permits and the other planned projects. This should ensure a mitigation of the otherwise negative impact on the bottom line.

Changes in forecasts. We cut our forecasts from the previous fair value update. The reason for this downwards adjustment is related to the issue with the unsold apartments. In our previous assumptions, we did not consider the company may face the issue. The difference in 2025E and 2026E forecasts is related to the time it will take to sell the apartments, as well as the pre-sales and sales period of the upcoming developments, in relation to G&A and marketing expenses.

Dividends: We expect a 0.0% payout ratio in 2025E and 10% in 2026E, implying RON 0 ps in 2025E and RON 0.001 ps in 2026E, implying a DY 0.4% and 0.4%.

Figure 1. Summary of financial data

RON m	2022	2023E	2024E	2025E	2026E	2027E
Revenues	219	169	255	566	660	726
EBITDA	111	43	23	49	58	66
EBIT	-6	-23	-33	-16	-33	-16
Net profit	86	37	-21	23	17	36
Dividends	0	3	0	0	2	2
EPS (RON)	0.04	0.01	-0.01	0.01	0.01	0.02
DPS (RON)	0.00	0.00	0.00	0.00	0.00	0.00
EV/EBITDA (x)	4.9	6.1	16.6	8.8	7.6	6.9
P/E (x)	10.4	17.9	-26.9	25.6	35.7	16.6
Dividend yield (%)	0.0%	0.5%	0.0%	0.0%	0.4%	0.4%

Source: Company, BVB, IPOPEMA Research*out of previous year's earnings

Real Estate


Impact

HOLD

FV RON 0.20 from RON 0.18

5.5% upside

Price as of 6 December 2024 RON 0.19



Share data

Number of shares (m)	2,364.9
Market cap (EUR m)	81.1
12M avg daily volume (k)	503.8
12M avg daily turnover (EUR m)	0.02
12M high/low (RON)	0.3/0.2
BET weight	0.00%
Reuters	ROIMP.BX
Bloomberg	IMP RO

Total performance

1M	-4.23%
3M	-8.33%
12M	-18.78%

Shareholders

Gheorghe laciu	58.03%
Others	41.97%

Analyst

Ionut Gavris ionut.gavris@ipopema.pl +48 665 340 021

Impact Deve	elon	er &	Cont	racto	r	P&L (RON m)	2021	2022	2023	2024E	2025E	2026E
iiii pace Bev	СІОР	· ·		·······	•	Total revenue	138.1	226.5	169.5	254.5	565.6	660.3
HOLD	FV U.ZU RON		Operating revenues	137.6	219.2	169.5	254.5	565.6	660.3			
Mkt Cap RON 455.0m			l Incido/	downsid	o +E E04	Other income and gains from IP OPEX	87.2 -38.3	85.0 -46.6	32.6 -59.9	0.0 -40.7	0.0 -52.8	0.0 -65.3
WIKE Cap KON 455.0111			opside/i	uowiisiu	e +3.3%	EBITDA	99.9	111.4	43.1	22.9	-32.8 49.4	58.4
						Depreciation	-1.2	-2.3	-4.1	-6.6	-4.0	-4.1
						EBIT	98.7	109.1	39.0	16.3	45.4	54.3
Valuation multiples	2022	2023	2024E	2025E	2026E	Net interest expense	-3.5	-6.2	-23.3	-33.4	-16.4	-33.4
P/E (x)	10.4	17.9	-26.9	25.6	35.7	Pre-tax profit	95.3	102.8	15.7	-17.1	29.0	20.9
EV/EBITDA adj (x)	4.9	6.1	16.6	8.8	7.6	Income tax	-16.5	-18.1	19.2	-6.1	-4.6	-3.3
EV/Sales (x)	2.5	1.6	1.3	0.8	0.7	Minorities	0.0	-0.9	-2.3	-1.8	1.2	0.9
P/BV (x)	1.0	0.7	0.7	0.7	0.7	Net profit	78.8	85.6	37.2	-21.5	23.2	16.7
FCF yield (%)	-8.0	32.2	30.6	27.3	9.0	•						
DY (%)	0.0	0.5	0.0	0.0	0.4	BALANCE SHEET (RON m)	2021	2022	2023	2024E	2025E	2026E
Payout ratio	0.0	4.0	0.0	0.0	10.0	Non-current assets	587.3	727.8	772.6	769.3	772.8	776.2
						Net fixed assets	15.2	65.6	88.8	87.8	89.9	91.9
Per share	2022	2023	2024E	2025E	2026E	Investment property	571.9	653.7	676.3	677.6	677.6	677.6
No. of shares (m units)	2,366	2,366	2,366	2,366	2,366	Intangibles and goodwill	0.2	4.1	4.2	3.7	4.1	4.6
EPS (RON)	0.04	0.01	-0.01	0.01	0.01	Others	0.0	4.3	3.3	0.2	1.2	2.0
BVPS (RON)	0.38	0.39	0.38	0.39	0.40	Current assets	617.1	715.6	694.8	686.5	728.6	741.3
FCFPS (RON)	-0.02	0.04	0.04	0.05	0.02	Cash and equivalents	42.0	55.1	51.3	118.5	218.2	220.2
DPS (RON)	0.00	0.00	0.00	0.00	0.00	Receivables	36.1	42.8	20.1	19.2	27.9	36.2
						Inventories	538.9	617.7	623.4	528.1	443.7	444.4
Change yoy (%)	2022	2023	2024E	2025E	2026E	Other current assets	0.0	0.0	0.0	20.8	38.7	40.5
Operating revenue	41.8%	-6.1%	-14.1%	72.4%	21.8%	Total assets	1,204.4	1,443.4	1,467.4	1,455.9	1,501.4	1,517.5
EBITDA	11.5%	-61.3%	-46.8%	115.8%	18.2%	Equity	716.9	879.8	911.2	892.5	915.6	930.0
EBIT	10.5%	-64.2%	-58.3%	179.2%	19.4%	Minorities	0.0	9.9	13.9	5.9	7.1	8.0
Net profit	8.7%	-56.6%	-157.8%	-207.9%	-28.1%	Non-current liabilities	225.5	358.4	410.9	285.0	296.3	307.1
Tax rate	19.0%	-18.7%	39.1%	-27.2%	11.5%	Interest bearing debt	150.1	268.9	347.0	196.5	206.5	214.0
						Payables	6.9	8.5	6.0	18.5	24.8	28.1
						Others	68.5	81.1	57.9	70.0	65.0	65.0
Leverage and return	2022	2023	2024E	2025E	2026E	Current liabilities	262.0	195.4	131.4	272.5	282.3	272.3
Operating margin	49.8%	23.0%	6.4%	8.0%	8.2%	Interest bearing debt	186.9	119.9	66.6	215.0	205.0	190.0
EBITDA margin	50.8%	25.4%	9.0%	8.7%	8.8%	Payables	73.8	33.7	23.4	13.2	17.7	22.2
EBIT margin	49.8%	23.0%	6.4%	8.0%	8.2%	Contract liabilities	0.0	39.5	38.9	39.6	53.2	51.8
Net debt/EBITDA (x)	3.0	8.4	12.8	3.9	3.1	Others	1.3	2.2	2.5	4.7	6.3	8.3
Net debt/Equity	0.4	0.4	0.3	0.2	0.2	Equity and liabiltiies	1,204.4	1,443.4	1,467.4	1,455.9	1,501.4	1,517.5
Net debt/Assets	0.2	0.2	0.2	0.1	0.1							
ROE	9.6%	4.0%	-2.4%	2.5%	1.8%	Gross debt	337.0	388.8	413.6	411.5	411.5	404.0
ROA	5.9%	2.5%	-1.5%	1.5%	1.1%	Net debt	295.0	333.7	362.3	293.0	193.3	183.7
A	2022	2022	20245	20255	2026E	CASFH FLOW (RONm)	2021	2022	2023	2024E	2025E	2026E
Assumptions	2022	2023	2024E			Cash flow from operating activities		-49.3	22.3	110.8	123.6	49.2
Operating revenues	219.2	169.5	254.5	565.6	660.3	Profit for the period	78.8	84.8	37.2	-19.2	24.4	17.5
Sales of apartments	219.2	169.5	254.5	565.6	660.3	Depreciation and amortization	0.8	2.3	4.1	3.8	4.0	4.1
Cost of sales	-148.5	-103.1	-197.5	-467.4	-540.7	Changes in WC	-69.6	-91.2	-0.3	88.5	83.5	-2.5
G&A	-30.2	-42.8	-29.2	-42.4	-56.8	Other, net	-62.2	-45.2	-18.7	37.7	11.8	30.1
Manaina (0) af nau)	2022	2022	20245	20255	20265	Cash flow from investment	-38.3	-55.7	-15.5	-12.0	-7.5	-7.5
Margins (% of rev)	2022	2023	2024E	2025E	2026E	Additions to PPE and intangibles Expenses on investment property	-0.3 -30.5	-45.1 -9.7	-5.9 -10.0	-12.6 0.0	-7.5 0.0	-7.5 0.0
Selling expenses	13.8%	25.2%	11.5%	7.5%	8.6%							
Depreciation	1.1%	2.4%	2.6%	0.7%	0.6% 9.9%	Other, net Cash flow from financing	-7.4 73.5	-0.8 118.1	0.3 -10.6	0.6 - 31.6	0.0 -16.4	0.0 -39.7
Total operating exp.	21.3%	35.3%	16.0%	9.3%	9.9%	-						
VDIc	2022	2022	20245	20255	20265	Changes in debt	80.1	60.7	22.2	-4.0	0.0	-7.5
Apartments sold	2022	2023	2024E	2025E	2026E	Dividends paid	0.0	0.0	-3.4	0.0	0.0	-2.3
Apartments sold	275	157	165	350	400	Proceeds from share capital Other, net	0.0 -6.6	77.7 -20.3	0.0 -29.3	0.0 -27.6	0.0 -16.4	0.0
Sqm sold	16,582	13,733	13,847	24,500	26,000			-20.3 13.1	-29.3 - 3.8	-27.6 67.2	99.7	-29.8 2.1
Price per sqm growth	59.3%	-6.6% 87.5	49.0%	25.6%	10.0%	Net change in cash and equivalent						
Average sqm/apartment Cost per sqm growth	60.3 69.3%	87.5 -16.2%	83.9 90.0%	70.0 33.7%	65.0 9.0%	Beginning cash and equivalents Ending cash and equivalents	59.0 42.0	42.0 55.1	55.1 51.3	51.3 118.5	118.5 218.2	218.2 220.2
cost per squi growni	05.570	10,470	20.070	70 ، ۱ ، د د	5.070	Ename cash and equivalents	72.0	33.1	31.3	110.3	210.2	220.2

Source: Company data, IPOPEMA Research

Figure 2. Valuation summary

Ron m	-	2024E	2025E	2026E	2027E	2028E	Terminal year
Risk free rate		6.5%	6.5%	6.5%	6.5%	6.5%	6.5%
Unlevered beta		1.0	1.0	1.0	1.0	1.0	1.0
Beta		2.1	1.7	1.7	1.7	1.7	1.7
Rm-Rf		7.5%	7.5%	7.5%	7.5%	7.5%	7.5%
Cost of equity (CAPM)		22.4%	19.2%	19.1%	19.2%	19.2%	19.2%
Debt premium		1.0%	1.0%	1.0%	1.0%	1.0%	1.0%
Pre-tax cost of debt		7.5%	7.5%	7.5%	7.5%	7.5%	7.5%
Tax rate		-35.8%	16.0%	16.0%	16.0%	16.0%	16.0%
After tax cost of debt		10.2%	6.3%	6.3%	6.3%	6.3%	6.3%
Debt share		45.3%	45.3%	44.8%	45.0%	45.5%	45.5%
Equity share		54.7%	54.7%	55.2%	55.0%	54.5%	54.5%
WACC		16.9%	13.4%	13.4%	13.4%	13.4%	13.4%
Revenues		254.5	565.6	660.3	726.3	795.3	874.8
EBIT		16.3	45.4	54.3	61.3	87.6	125.0
Tax rate		-35.8%	16.0%	16.0%	16.0%	16.0%	16.0%
NOPLAT		22.1	38.2	45.6	51.5	73.6	105.0
Depreciation		3.8	4.0	4.1	4.3	4.4	7.9
CAPEX		-12.6	-7.5	-7.5	-7.5	-7.5	-4.4
Change in working capital		88.5	83.5	-2.5	-13.1	-4.9	-6.8
Leasing payments		-1.0	-1.5	-2.0	-2.5	-3.0	-3.5
FCF		100.8	116.6	37.7	32.6	62.6	98.1
Discount factor		1.0	0.9	0.8	0.7	0.6	
PV of Free Cash Flow		99.6	101.7	29.0	22.1	37.4	
Sum of PV FCFs	289.8						
Terminal growth	3.0%						
Terminal value	947.3						
PV of terminal value	566.7						
Enterprise value	856.5						
Net debt	362.3						
Dividends paid	0.0						
Minorities	13.9						
Equity value	480.3						

Source: Company, IPOPEMA Research

NOSH

FV (RON)

Upside

Current price

Figure 3. Sensitivity analysis

2365.7

0.20

0.19

5.5%

				EBIT margin		
		12.5%	13.0%	13.6%	14.0%	14.5%
	2.0%	0.18	0.18	0.18	0.18	0.18
	2.5%	0.19	0.19	0.19	0.19	0.19
g rate	3.0%	0.20	0.20	0.20	0.20	0.20
	3.5%	0.22	0.22	0.22	0.22	0.22
	4.0%	0.23	0.23	0.23	0.23	0.23

Source: IPOPEMA Research

Figure 4. Impact Developer & Contractor changes in forecasts

	New	Old	Ch.%	New	Old	Ch.%	New	Old	Ch.%
P&L Summary (RON m)	2024E	2024E		2025E	2025E		2026E	2026E	
Revenue	254.5	165.9	53.4%	565.6	181.0	212.5%	660.3	197.5	234.3%
OPEX and gains	-40.7	-63.3	-35.7%	-52.8	-68.7	-23.2%	-65.3	-55.0	18.8%
EBITDA	22.9	102.7	-77.7%	49.4	112.3	-56.0%	58.4	142.5	-59.0%
Depreciation	-6.6	-3.6	86.5%	-4.0	-3.7	6.3%	-4.1	-4.0	4.0%
EBIT	16.3	99.1	-83.6%	45.4	108.6	-58.1%	54.3	138.6	-60.8%
Net other	-33.4	-15.7	112.7%	-16.4	-14.9	9.8%	-33.4	-13.2	153.5%
Pre-tax profit	-17.1	83.4	-120.5%	29.0	93.7	-69.0%	20.9	125.4	-83.3%
Net profit	-21.5	70.1	-130.7%	23.2	78.7	-70.5%	16.7	105.3	-84.2%

Source: IPOPEMA Research



Figure 5. Impact Developer & Contractor peer comparison

Name	Ticker	Price (local)		P/E		EV	/EBITDA	
			2024E	2025E	2026E	2024E	2025E	2026E
One United Properties	ONE RO Equity	0.4	6.72	4.48	4.03	5.2	4.3	3.2
Dom Development	DOM PW	209.0	9.58	8.98	8.06	7.8	7.1	6.6
Atal	1AT PW	52.9	8.09	6.60	6.08	7.6	6.5	6.4
Archicom	ARH PW	35.3	20.55	9.95	4.58	13.9	7.8	3.6
Inmobiliaria Del Sur	ISUR SM	9.2	9.29	4.84	10.76	12.1	7.0	10.3
Median			9.29	6.60	6.08	7.76	7.04	6.41
Premium / discount to median			N/A	288.6%	487.0%	113.8%	24.3%	18.1%

Source: Bloomberg, IPOPEMA Research

This document has been prepared by IPOPEMA Securities S.A. with its registered seat in Warsaw, Próżna 9, 00-107 Warsaw, Poland, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the City of Warsaw, XII Commercial Division of the National Court Register under entry number KRS 0000230737, the initial capital and paid capital in the amount of PLN 2.993.783,60, NIP 5272468122, www.ipopema.pl. IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Piękna 20, 00-549 Warsaw, Poland.

This document was prepared by IPOPEMA Securities S.A. for information purposes only. This document is addressed to IPOPEMA Securities S.A. clients entitled to receive it on the basis of contracts for the provision of services. This document, using mass media distribution channels, may also reach other investors. It has been produced independently of the company mentioned in this document and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise specified, the estimates and opinions contained in the document constitute an independent assessment of IPOPEMA Securities S.A. analysts preparing the document as of the date of issuing the document.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness and reliability on the basis of publicly available information which IPOPEMA Securities S.A. believes to be reliable. The sources of data are primarily: Bloomberg, Reuters, EPFR, Polska Agencja Prasowa, WSE, Główny Urząd Statystyczny, Narodowy Bank Polski, financial press, online financial and economic services. While due diligence has been taken by IPOPEMA Securities S.A. to ensure that the facts stated herein are accurate and than any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed in the document can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinion current. None of the IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith provided that IPOPEMA Securities S.A. has been exercised due diligence and integrity during its preparation. This document may be sent to the mass media, however its copying or publishing in whole or in part as well as dissemination of information enclosed to it is allowed only with prior permission of IPOPEMA Securities S.A. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada, Serbia or Japan, subject to the following section.

Important disclosures for U.S. Persons: Auerbach Grayson & Company Inc. may distribute this document in the U.S. This document is provided for distribution to Major U.S. Institutional Investors in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended and may not be furnished to any other person in the U.S. Each Major U.S. Institutional Investor that receives this document shall not distribute or provide it to any other person. Under no circumstances should any U.S. recipient of this document effect any transaction to buy or sell securities or related financial instruments through IPOPEMA Securities S.A. Any U.S. recipient of this document wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this document should do so only through Auerbach Grayson & Company Inc. 25 West 45th Street, Floor 16, New York, NY 10036 U.S. which is a registered broker dealer in the U.S. IPOPEMA Securities S.A. is not a registered broker-dealer in the U.S. and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. IPOPEMA Securities S.A. and its research analysts are not associated persons of Auerbach Grayson & Company, nor are they affiliated with Auerbach Grayson & Company. The author of this document whose name appears in this document is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"), is not subject to the SEC rules on research analysts and is not subject FINRA's rules on debt research analysts and debt research reports, equity research analysts and equity research reports. U.S. recipients should take into account that information on non-U.S. securities or related financial instruments discussed in this document may be limited. The financial instruments of non-U.S. issuers may not be registered with, or be subject to the regulations of, the SEC. Foreign c

This document does not constitute any offer to sell or induce any offer to buy or sell any financial instruments, cannot be relied on in connection with any contract or liability and does not constitute advertising or promotion of a financial instrument or the company. Investment decisions should only be made on the basis of a prospectus or other publicly available information and materials.

The document was prepared without taking into account the needs and situation of the recipients of the document. When preparing the document, IPOPEMA Securities S.A. does not examine the recipients' investment objectives, risk tolerance level, time horizon and financial standing of the investors. The company or the financial instruments discussed in the document may not be suitable for the users of the document, i.e. it may not be suitable for the specific objectives and time horizon or the financial situation. Information included in the document cannot be regarded as a substitute for obtaining investment advice service. The value of financial instruments may fluctuate, including declines. Changes in FX rates may have an adverse effect on the value of investments. The investment in financial instruments is linked to investment risks including loss of entire or part of the invested capital. Past performance is not necessarily indicative of future results. IPOPEMA Securities S.A. points out that the price of financial instruments is affected by many different factors that are or may be independent of the company and the results of its operations. These include, among others changing economic, legal, political and tax conditions. IPOPEMA Securities S.A. may have issued in the past or may issue other documents in the future, presenting other conclusions, not consistent with those presented herein document. Such documents reflect different assumptions, points of view and analytical methods adopted by the analysts preparing them.

Investors should be aware that IPOPEMA Securities S.A. or its related entities may have a conflict of interest that could affect this document's objectivity. The investor should assume that IPOPEMA Securities S.A. or its related entities may provide services in favour of the company and obtain remuneration on this account. They may also have another financial interest with respect to the company. IPOPEMA Securities S.A. or its related entities may seek to do business with the company or other entities mentioned in this document. IPOPEMA Securities S.A. has an organizational structure and internal regulations in place to ensure that the client's interests are not compromised in the event of a conflict of interests, in relation to preparing this document. Conflict of interest management policy is available on the website at https://www.ipopemasecurities.pl/analizy-i-rekomendacje.p162. This document was prepared irrespective and independently of the interests of IPOPEMA Securities S.A., the company that is the subject of this document and holder of financial instrument issued by aforementioned company. IPOPEMA Securities S.A., its shareholders, employees and associates may hold long or short positions in the company's financial instruments or other financial instruments related to the company's financial instruments.

On the order of the Warsaw Stock Exchange S.A. ("WSE"), IPOPEMA Securities S.A. creates analytical materials for the following companies: ATM Grupa S.A., Mirbud S.A., ML System S.A., Molecure S.A., PointPack S.A., Synektik S.A., Fabryka Farb i Lakierów Śnieżka S.A., Ultimate Games S.A., VIGO Photonics S.A. The WSE has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the WSE. Information on the program is available on the website https://www.gpw.pl/gpwpa.

On the order of the Bursa de Valori Bucuresti S.A. ("BVB"), IPOPEMA Securities S.A. creates analytical materials for the following companies: Bittnet Systems S.A., Impact Developer & Contractor S.A., OMV Petrom S.A. and Safetech Innovations S.A. The BVB has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the BVB.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the report's author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could results in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparator is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This document was not transferred to the company prior to its publication. This document was prepared according to the author's own view, assumptions and knowledge.

Recommendations issued by IPOPEMA Securities S.A. they are valid for a period of 12 months from the date of issue, unless they are updated during this period. IPOPEMA Securities S.A. updates the issued recommendations depending on the market situation and subjective analysts' assessment. In the last 12 months IPOPEMA Securities S.A. has not prepared any recommendation concerning the company.

This document is an investment research within the meaning of Art. 36 par. 1 of the Commission Delegated Regulation (EU) 2017/565.

List of all recommendations regarding any financial instrument or issuer that have been disseminated within the last 12 months by IPOPEMA Securities S.A. is available on the website at https://www.ipopemasecurities.pl/analizy-i-rekomendacie.p162.

The date and the time stated on the front page is the date of the preparation of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this document.



Romanian Equities

The definitions of terms used in the document include:

NII - Net interest income - interest income minus interest expense.

Net F&C - Net fee and commission income - fee and commission income minus fee and commission expense.

LLP - loan loss provisions - an expense set aside as an allowance for bad loans.

NPL - non-performing loan - loans that are in default or close to be in default.

Cost/Income – operating expenses divided by total banking revenue.

ROE – return on equity – net income (or adjusted net income) divided by the average shareholders' equity.

ROA – return on assets – net income (or adjusted net income) divided by the average assets.

EBIT - earnings before interests and tax.

EBITDA – earnings before interests, tax, depreciation and amortization.

EPS – earnings per share – the net income (or adjusted net income divided by the number of shares outstanding.

P/E - price to earnings ratio - price divided by earnings per share.

PEG – P/E ratio divided by the annual EPS growth, usually over a certain period of time.

CAGR - compound annual growth rate.

BVPS – book value per share, the book value of the Company's equity divided by the number of shares outstanding.

P/BV - price to book value - price divided by the BVPS.

DPS – dividend per share – dividend of a given year divided by the number of shares outstanding.

DY - dividend yield - dividend of a given year divided by the current price.

DDM - dividend discount model - a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends.

FV – Fair Value, calculated based on valuation methods outlined in the document.

The author of this document has no conflict of interest with the company that is the subject of this document. The point of view expressed in the document reflects the personal opinion of the author of the document on the analyzed company and its financial instruments. Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.

IPOPEMA Securities S.A. shall act with due diligence, honestly, fairly, professionally and in accordance with the provisions of the applicable law.

IPOPEMA Securities S.A. does not guarantee achieving the investor's investment objective, the performance of company or prospective prices referred to herein.

When applying ratings for companies following criteria are used with regards to the difference between IPOPEMA'S FV and company's price at the date of recommendation:

Rating	Difference between FV and price at recommendation
Buy	Above 10%
Hold	In between (and including) -10% and 10%
Sell	Below -10%

IPOPEMA Research - Distribution by rating category (1 July – 30 S	eptember 2024)	
	Number	%
Buy	18	56%
Hold	8	25%
Sell	6	19%
Total	32	100%

Rating History - Impact Developer & Contractor								
Date	Recommendation	Fair Value	Price at recommendation	Author				
29/03/2021	BUY	RON 3.40	RON 2.88	Florin Ciocoi				
19/07/2021	BUY	RON 0.61	RON 0.52	Florin Ciocoi				
27/07/2022	BUY	RON 0.87	RON 0.65	Florin Ciocoi				
30/08/2022	BUY	RON 0.52	RON 0.45	Florin Ciocoi				
12/12/2022	HOLD	RON 0.41	RON 0.39	Florin Ciocoi				
31/06/2023	BUY	RON 0.32	RON 0.28	Florin Ciocoi				
06/12/2024	BUY	RON 0.20	RON 0.19	lonut Gavris				

